Cloning and expression of an HTLV gag-related autoantigen (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Cloning and expression of an HTLV gag-related autoantigen (Meeting abstract).

FASEB J; 6(4):A1119 1992. Unique Identifier : AIDSLINE ICDB/93687051
Banki K; Brachmann J; Hung C; Mattson D; Ablonczy E; Perl A; RPMI, Buffalo, NY 14263

Abstract: We cloned a second human T-cell leukemia virus-related endogenous sequence (HRES-2), which is distinct from HRES-1 (NAR 17:6841-54, 1989). An HRES-2 cDNA was expressed in a prokaryotic vector. Recombinant HRES-2 protein was used to generate specific antibodies. HRES-2-specific antibodies identified the native protein, a 35-kD doublet in various human cell types expressing a 6.5-kb HRES-2-specific transcript. The GC-rich regions, explaining cross-hybridization between HRES-2, HRES-1 and HTLV-I, translate into proline-rich amino acid sequences in HRES-2 and gag of HTLV-I/HTLV-II. The amino acid homologies between these sequences comprise cross-reactive antigenic epitopes: a HRES-2 protein. Sera of patients with systemic sclerosis and sera and cerebrospinal fluid of patients with multiple sclerosis react with recombinant HRES-2 protein. The data suggest that the HRES-2 protein may be an autoantigen responsible for eliciting HTLV-reactive autoantibodies.

Keywords: Amino Acid Sequence Autoantibodies/*ANALYSIS/GENETICS *Cloning, Molecular *Gene Expression Gene Products, gag/*ANALYSIS/GENETICS HTLV-I Antigens/*ANALYSIS/GENETICS Recombinant Proteins/ANALYSIS/GENETICS ABSTRACT
930228
M9320867

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .